Bristol-Myers Squibb Posts Solid Q1 Results With the Celgene Acquisition Looming

The last time Bristol-Myers Squibb (NYSE:BMY) announced its quarterly results, there were several positives for investors. Revenue increased 10% year over year, while earnings soared by 38%.

Bristol-Myers Squibb provided its first-quarter update before the market opened on Thursday. The big pharma company yet again had plenty of good news for investors. Here's what you need to know about the company's Q1 results.